BWX Technologies, Inc. (BWXT) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary shows strong strategic developments, including backlog growth, new contracts, and expansion plans, indicating positive future prospects. The Q&A section reveals proactive measures addressing bottlenecks and strategic partnerships, with analysts showing interest in nuclear and microreactor markets. Despite some uncertainties, the guidance remains optimistic, with a focus on revenue growth and margin expectations. The overall sentiment leans towards positive, suggesting a stock price increase over the next two weeks.
Key Financial Performance
Backlog $6 billion, up 23% quarter-over-quarter and 70% year-over-year. Growth driven by both segments.
Government Operations Revenue Up 9% year-over-year. Growth driven by strong execution, particularly within the special materials portfolio, the A.O.T. acquisition, and timing of material procurement.
Government Operations Adjusted EBITDA Up 23% year-over-year. Driven by favorable mix, strong operating performance, and favorable contract performance in the special materials portfolio.
Government Operations Backlog $4.4 billion, up 24% sequentially and 55% year-over-year. Growth driven by over $1 billion in orders on a naval nuclear reactor components contract.
Commercial Operations Revenue $176 million, up 24% year-over-year. Growth driven by the Kinectrics acquisition and double-digit growth in Medical, offset by a modest decline in commercial power due to timing of outage and maintenance projects.
Commercial Operations Adjusted EBITDA $16 million, down from $23 million last year. Decline due to unfavorable mix, lower field services revenue, and growth investment to match market demand.
Total Company Revenue $764 million, up 12% year-over-year. Growth driven by both segments, with organic revenue up 4% excluding acquisitions.
Adjusted EBITDA $146 million, up 16% year-over-year. Growth driven by robust double-digit growth in government operations, partially offset by lower adjusted EBITDA in commercial operations.
Adjusted Earnings Per Share (EPS) $1.02, up 24% year-over-year. Growth driven by strong operating performance, lower tax rate, foreign currency gains, and higher pension income, partially offset by higher interest expense.
Free Cash Flow $126 million, driven by good working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Microreactors: Began manufacturing the reactor core for Pele, a land-based transportable microreactor, aligned with the President's National Security Executive Order.
Medical isotopes: Canadian Nuclear Safety Commission approved irradiation of deuterium-90 and lutetium-177, supporting over 20% growth in medical isotopes.
Kinectrics acquisition: Acquired Kinectrics, adding 1,300 employees and expanding life of plant services in nuclear power and energy infrastructure markets.
International expansion: Selected to manage Canadian Nuclear Laboratories, marking the first international project in this line of business with an annual contract value of CAD 1.2 billion.
Government Operations: Revenue up 9%, adjusted EBITDA up 23%, driven by strong execution and material procurement timing.
Commercial Operations: Reported revenue growth of 24%, with mid-teens organic growth expected for the year.
Naval nuclear reactor components: Signed an $2.6 billion agreement over 8 years for Virginia and Columbia class submarines and Ford-class aircraft carriers.
Advanced nuclear fuel: Tracking opportunities for advanced nuclear fuel for defense and commercial applications, including defense uranium enrichment pilot plant.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Licensing Challenges: The company is working on obtaining licenses and approvals for projects such as the defense uranium enrichment pilot plant and the irradiation of medical isotopes. Delays or failures in obtaining these approvals could impact project timelines and revenue.
Supply Chain and Material Procurement Risks: The timing of material procurement has been highlighted as a factor in revenue and operational performance. Any disruptions in the supply chain could adversely affect production schedules and financial outcomes.
Market Demand and Competitive Pressures: While demand in nuclear power and medical isotopes is growing, the company faces competitive pressures in securing contracts, particularly in the SMR and advanced nuclear fuel markets.
Execution Risks in Large-Scale Projects: The company is involved in complex projects like the Pele microreactor and Canadian Nuclear Laboratories. Any delays or cost overruns in these projects could impact financial performance and reputation.
Economic and Currency Risks: Foreign currency gains contributed to financial performance this quarter. However, fluctuations in currency exchange rates could pose risks to future earnings.
Field Services Revenue Decline: Field services, a high-margin business line, saw a significant revenue decline, impacting overall segment margins. This could be a concern if the trend continues.
Capital Expenditure and Growth Investments: The company is increasing capital expenditures to meet market demand, which could strain cash flow if revenue growth does not materialize as expected.
Dependence on Government Contracts: A significant portion of revenue comes from government contracts, particularly in naval propulsion and national security. Changes in government priorities or funding could impact these revenue streams.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: BWXT raised its 2025 revenue guidance to approximately $3.1 billion, reflecting modestly better revenue assumptions across the business and contributions from the Kinectrics acquisition.
Adjusted EBITDA Guidance: The company increased its adjusted EBITDA guidance to $565 million to $575 million, up $10 million at the midpoint, driven by stronger operational performance in government operations and slightly higher revenue in commercial operations.
Earnings Per Share (EPS) Guidance: BWXT raised its adjusted EPS guidance to $3.65 to $3.75 per share, up about $0.23 at the midpoint, with half of the increase driven by operations and half by non-operating items such as a lower tax rate and better pension and other income.
Free Cash Flow Guidance: The company increased its free cash flow guidance to $275 million to $285 million, up $10 million at the low end, supported by higher income and benefits from tax legislation, partially offset by slightly higher CapEx.
Government Operations Revenue Growth: BWXT expects mid-single-digit revenue growth in government operations for 2025, with adjusted EBITDA margin anticipated to be approximately 20.5% for the year.
Commercial Operations Revenue Growth: The company expects commercial operations revenue to grow over 50%, with mid-teens organic growth complemented by the Kinectrics acquisition. Adjusted EBITDA margin is expected to be 13.5% to 14%.
Capital Expenditures: Capital expenditures are expected to be 5.5% to 6% of sales for 2025, driven by investments to meet growing end-market demand, including the expansion of the Cambridge commercial nuclear manufacturing facility and infrastructure investments related to defense fuels and government operations.
Medical Segment Growth: BWXT Medical is projected to achieve over 20% growth in 2025, driven by robust demand for diagnostic and therapeutic isotopes.
Microreactors and Advanced Nuclear Fuel: BWXT is progressing on manufacturing the reactor core for the Pele microreactor, with operations expected by September 2028. The company is also tracking advanced nuclear fuel opportunities for defense and commercial applications.
Small Modular Reactors (SMRs): BWXT is actively bidding on component engineering and manufacturing contracts for SMRs, including the GE Hitachi BWRX-300 and other designs, with expectations of multiple follow-on orders in the coming years.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you clarify the $29 million favorable contract adjustment on nuclear operations mentioned in the 10-Q?
A:The $29 million relates to one of the Special Materials contracts. A portion of it was included in the original guidance, but it turned out to be more favorable than anticipated.
Q:Do you see any opportunity for BWXT to secure content on new build AP1000s in the U.S., and what type of content would the company compete for?
A:BWXT has an MOU with Westinghouse to potentially manufacture components for the AP1000 in the U.S. and other markets. This includes high-pressure components like steam generators, heat exchangers, and reactor pressure vessels.
Q:Could your content on AP1000 reactors be as large as CANDU?
A:It is unlikely. While the scope of equipment is similar, BWXT does not expect to secure as much content as it does with CANDU reactors.
Q:What is the mandate of Kevin McCoy as Chief Nuclear Officer, and how will he influence bottlenecks?
A:Kevin McCoy is seconded to the Department of Defense to assist with nuclear shipbuilding. His title at BWXT is a placeholder while he works under contract with the Navy. Joe Miller has been promoted to President of Government Operations to replace him.
Q:What drove the government operations margins of approximately 20.5%?
A:The margin was impacted by the EAC for the special materials contract, good pacing of work, and timing of materials. Efficiencies and utilization at the plants also contributed to the strong performance.
Q:What is the opportunity related to the recent approval by the CNSC to irradiate deuterium and lutetium?
A:BWXT is partnering with Laurentis Energy Partners. The qualification of these products is up to Laurentis, and BWXT will earn royalties from the target delivery system it designed and deployed.
Q:How does BWXT prioritize capital allocation for opportunities like SMR growth and Pele build-out?
A:BWXT allocates 4%-6% of sales for CapEx, with episodic surges for specific projects like the Cambridge plant build-out. Investments are evaluated based on business cases, with a focus on high-quality opportunities.
Q:How far are you contracted for Navy programs?
A:The contracts have a performance period of up to 8 years, with full ship set deliveries typically taking 6-8 years.
Q:How much did Kinectrics contribute to the guidance increase, and what are the assumptions for working capital?
A:Kinectrics contributed a small portion to the guidance increase, as its EPS impact is neutralized by additional interest expenses. Working capital and free cash flow generation are expected to be over 80% for Kinectrics.
Q:What is motivating the Navy to issue larger awards in a compressed time frame?
A:The Navy aims to keep the supply chain running at pace while addressing shipyard bottlenecks. The recent pricing agreement validates this approach, maintaining the 30-year shipbuilding plan.
Q:Are the advanced nuclear fuel opportunities largely government-related?
A:Not entirely. There is commercial interest in TRISO fuel, and BWXT expects to secure contracts this year. Additionally, the defense enrichment program could have commercial outlets.
Q:What is the outlook for the microreactor market, including Pele and DRACO?
A:Pele is progressing, with potential for production programs at multiple DoD sites. DRACO is continuing under NASA, with significant appropriations. Other programs like JETSON and fission surface power also show promise.
Q:Would BWXT consider taking more work off shipyards to address bottlenecks?
A:BWXT is not highly interested in non-nuclear qualified components, which most of this work would involve.
Q:Are there further impacts related to zirconium supply?
A:Zirconium pricing has leveled out, and BWXT does not accept commodity risk in its contracts, passing it through to customers.
Q:Can you quantify the engagement level in BWXT's markets compared to a year ago?
A:While specific metrics were not provided, BWXT sees high activity across all end markets, including medical, government, and commercial power.
Q:What is the financial impact of TRISO fuel contracts?
A:The contracts are small but strategically significant, with modest demand emerging on the commercial side.
Q:What is the impact of the reconciliation bill on BWXT?
A:The bill supports programs like a second Virginia for 2026, defense enrichment, advanced reactors, and the Strategic Capabilities Office, benefiting BWXT's ongoing projects.
Q:What is the revenue recognition profile for the first BWRX-300 reactor at Darlington?
A:The opportunity per reactor is around $100 million, with revenue evenly distributed over a 4-year period. The timing for TVA reactors is uncertain but could overlap with Darlington's additional reactors.
Q:Why does the guidance assume lower government operations revenue and margins in the second half?
A:The first half saw strong overperformance due to advanced material procurements and special materials contract performance. The second half is expected to normalize.
Q:How much of the backlog growth is organic versus acquisition-related?
A:The majority of the backlog growth is organic, with about $240 million attributed to acquisitions.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the financial impact of TRISO fuel contracts, stating they are smallish and strategically significant but not big economically yet. Additionally, they did not clarify the exact timing or scale of advanced nuclear fuel opportunities or the precise revenue cadence for TVA reactors.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Accounting Officer
Backlog segment
Canadian Nuclear
Chief Accounting
Commercial
Darlington site
Finance
GE Hitachi
Government
Kinectrics acquisition
LLC Research
Partners
Research Division
SMR market
Securities Inc
Strategic
acquisition digit
acquisition margin
aircraft carrier
book bill
contribution Kinectrics
decline power
engineering
field service
infrastructure
maintenance project
market demand
material portfolio
midpoint
outage maintenance
power component
rate tax
BWXT Transcript
BWX Technologies, Inc. (BWXT) Q1 2026 Earnings Call Transcript
Unknown5-5
The earnings call summary presents a mixed picture. While there are positive elements such as strong growth in the Medical segment and unique positioning in TRISO fuel production, there are concerns about delivery risks in nuclear projects and high CapEx. The Q&A section highlights uncertainties, such as unclear timelines for key projects and potential delivery risks, which could weigh on investor sentiment. Without a clear market cap, it's challenging to gauge the exact impact, but the presence of both positive and negative factors suggests a neutral stock price movement.
BWX Technologies, Inc. (BWXT) Q4 2025 Earnings Call Transcript
Positive2-23
The earnings call highlighted strong financial performance with record revenue and significant growth in operating income, net income, and free cash flow. The strategic outlook for 2026 is optimistic, with expectations of continued growth in key segments like government and commercial operations. While there are risks associated with forward-looking statements and reliance on non-GAAP measures, the overall sentiment is positive. The absence of shareholder return plans does not significantly impact the positive outlook due to strong financial metrics and optimistic guidance.
BWX Technologies, Inc. (BWXT) Q3 2025 Earnings Call Transcript
Positive11-3
The earnings call summary and Q&A session indicate strong financial metrics with raised guidance across revenue, EBITDA, EPS, and free cash flow. The Kinectrics acquisition and government/commercial operations show promising growth. Despite some risks, such as lower initial margins and delayed Project Pele delivery, the market strategy with SMRs and medical segment growth is optimistic. The positive sentiment is further supported by the strategic partnerships and opportunities in nuclear energy. Overall, the outlook suggests a positive stock price movement, likely in the 2% to 8% range.
BWX Technologies, Inc. (BWXT) Q2 2025 Earnings Call Transcript
Positive8-4
The earnings call summary shows strong strategic developments, including backlog growth, new contracts, and expansion plans, indicating positive future prospects. The Q&A section reveals proactive measures addressing bottlenecks and strategic partnerships, with analysts showing interest in nuclear and microreactor markets. Despite some uncertainties, the guidance remains optimistic, with a focus on revenue growth and margin expectations. The overall sentiment leans towards positive, suggesting a stock price increase over the next two weeks.
BWXT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
